Open AccessClinical use of Dexamethasone Implants in Resistant Macular Edema Secondary to Branch Retinal Vascular Occlusion compared with Intravitreal Anti-Vascular Endothelial Growth Factor
Author(s) -
Erdem Eriş
Publication year - 2019
Publication title -
beyoğlu eye journal (online)/beyoğlu eye journal
Language(s) - English
Resource type - Journals
eISSN - 2587-0394
pISSN - 2459-1777
DOI - 10.14744/bej.2019.63835
Subject(s) - medicine , macular edema , ranibizumab , branch retinal vein occlusion , ophthalmology , dexamethasone , visual acuity , retinal , retinal vein , bevacizumab , vascular endothelial growth factor , surgery , vegf receptors , chemotherapy
Branch retinal vein occlusion (BRVO) is the second most common type of retinal vascular disorder. Both inflammation and increased vascular endothelial growth factor (VEGF) levels play important roles in the pathogenesis of macular edema (ME) secondary to BRVO. The aim of this study was to compare the efficacy of 0.7-mg intravitreal dexamethasone implants with continued anti-VEGF treatment in patients with ME secondary to BRVO who were poor responders to at least 6 previous anti-VEGF injections.